银质针导热疗法治疗肌筋膜疼痛综合征的临床安全性

目的:评价银质针导热疗法治疗肌筋膜疼痛综合征的临床安全性。方法:采用随机单盲方法观察378例肌筋膜疼痛综合征患者进行银质针导热疗法治疗前后血、尿、便常规、肝肾功能、心肌酶及心电图的变化;针刺前1h、局部麻醉即刻、局部麻醉后10min、针刺即刻和针刺治疗后1h动态检测心率、呼吸、血压、血氧饱和度变化。结果:银质针治疗前后患者血常规、尿常规、便常规、肝肾功能、心肌酶检测结果无显著性差异(P0.05);银质针导热疗法前、中、后动态检测心率、呼吸、血压、血氧饱和度变化结果显示,心率、呼吸、血压、血氧饱和度无明显异常变化。结论:经安全性系列研究证明:银质针导热疗法治疗肌筋膜疼痛综合征是安全的,使用于老年人和稳定期心脏病患者。

A research of safety of silver needle thermo-conduction therapy for myofascialgia syndrome

Objective: To evaluate the safety of silver needle thermo-conduction therapy for myofascialgia syndrome. Method: Three hundred and seventy-eight patients with myofascialgia syndrome were monitored before, during and after silver needle thermo-conduction treatment. The data concerned were recorded and analysed before and after treatment: blood, urine and feces routine examination, hepatic and renal functions, myocardiase measurement and electrocardiogram: and the indexes changes of heart beating rates, respiration, blood pressure and oxygen saturation of blood were monitored dynamically before, during and after silver needle thermo-conduction therapy and local anesthesia. Result: Before and after treatment, the results of blood, urine and feces routine examination, hepatic and renal functions and myocardiase were normal without obvious difference(P>0.05). No obvious abnormal change was found in the rest above-mentioned parameters during the monitoring. Conclusion: The silver needle thermo-conduction therapy for myofascialgia syndrome is safe and reliable. The therapy is also suitable for the elderly and the patients with heart diseases in stable stage.